Supplementary Tables S1-S3; Supplementary Figures S1-S3; and Supplementary Materials and Methods from Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression